Trial Profile
Effect of gimeracil/oteracil/tegafur (S-1) and biomarkers associated with treatment in patients with malignant-thymoma (thymic carcinoma)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2015
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- 02 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.